The personalized-medicine concept represents the future of oncology medicine. New genomics technologies will characterize patients biologically in ways that will drive more efficient and effective cancer treatment. Yet the introduction of these technologies is disruptive to current practices in clinical oncology, as well as to current regulatory and reimbursement strategies. The efficient introduction of personalized medicine will require education in addition to behavioral and policy changes by the various involved stakeholders.